Gregory Jones

6PUBLICATIONS
41CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 14, 2026
Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation.

Jonathan Baden, Cheng-Ho Jimmy Lin, Andrew T Anfora

|May 11, 2024
Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and Stages.

Brittany A McKelvey, Hillary S Andrews, Frederick L Baehner

|Mar 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.

Filipa Lynce, Candace Mainor, Renee N Donahue

|Jun 12, 2020
Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.

Jordi Remon, Aurelie Swalduz, David Planchard

|Dec 06, 2018
MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.

Monika E Hegi, Els Genbrugge, Thierry Gorlia

Pageof 1

Frequent Collaborators

2 joint publications

Rita Nanda

2 joint publications

Christopher Gallagher

2 joint publications

Jay Zeck

2 joint publications

Filipa Lynce